More News! 19 Sep 2017 Scottish Scientists Claim that the Genome Controls the Aging of the Brain …growing problem. If this is not enough motivation, the Alzheimer’s drug market is expected to be worth $6.4B (€5.4B) by 2025. Images – AjayTvm / shutterstock.com; graph taken from: http://www.forgetaboutalzheimers.com/about-alzheimers/… September 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2020 AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy company AskBio. AskBio’s gene therapy experience and… April 28, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease …long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether or not targeting amyloid-beta plaques,… January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
More News! 16 Nov 2018 AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund… November 16, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2017 A Dutch University Hospital has Halted Amyloid Beta Drug Studies …form plaques—one of the telltale signs of Alzheimer’s disease. Toxic amyloid built up has been the dominant theory of Alzheimer’s for almost three decades, but there is still no drug… February 10, 2017 - 3 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 The challenges of tackling dementia in women …in Alzheimer’s called amyloid beta may be linked to the brain’s immune system. Similarly, the menopause impacting estrogen levels might make women more vulnerable to Alzheimer’s. Among the environmental factors,… March 8, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2023 ‘Clinical trial in a dish’ for Alzheimer’s disease Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, has signed an agreement with StrataStem to access and commercialize its collection of Alzheimer’s disease (AD) patient samples. … June 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 …Headquartered in Aberdeen, TauRx Pharmaceuticals was founded in 2002 with the clear mission to improve the diagnosis, treatment and cure of neurodegenerative diseases caused by protein aggregation, with Alzheimer’s as… February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Nov 2024 Seven miRNA-focused companies pioneering new therapies in 2024 …aimed at treating neurodegenerative diseases. Founded in 2016, the company focuses on developing solutions for conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company’s lead candidate, BMD-001,… November 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Dec 2024 10 biotech companies to watch in 2025 …in 2025. Table of contents Anavex Life Sciences Lead candidate: blarcamesine, for neurodegenerative diseases Anavex submitted marketing authorization application for blarcamesine for treatment of Alzheimer’s Blarcamesine received FDA orphan drug… December 16, 2024 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2016 World Mental Health Day: How is Biotech Helping the Cause? …Alzheimer’s, while Parkinson’s affects 6.3 million people. Current treatments deal with symptoms but cannot stop the progression of the disease. We interviewed the CSO of the Dementia Discovery Fund earlier… October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech …huge relevance of Alzheimer’s in biotech. The Swiss company is currently running Phase III trials with crenezumab, which could become one of the first therapies for Alzheimer’s after the recent… December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email